Argos Therapeutics Participating in 4th International mRNA Health Conference
Nov 02, 2016 12:01 pm UTC| Business
DURHAM, N.C., Nov. 02, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Nov 02, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to...
Nov 02, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to...
Great Lakes Reports Third Quarter Results
Nov 02, 2016 12:01 pm UTC| Business
OAK BROOK, Ill., Nov. 02, 2016 -- Great Lakes Dredge Dock Corporation (NASDAQ:GLDD), the largest provider of dredging services in the United States and a major provider of environmental and infrastructure services,...
Great Lakes Reports Third Quarter Results
Nov 02, 2016 12:01 pm UTC| Business
OAK BROOK, Ill., Nov. 02, 2016 -- Great Lakes Dredge Dock Corporation (NASDAQ:GLDD), the largest provider of dredging services in the United States and a major provider of environmental and infrastructure services,...
Evogene Third Quarter 2016 Earnings Announcement Schedule
Nov 02, 2016 12:01 pm UTC| Business
REHOVOT, Israel, Nov. 02, 2016 -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third...
Evogene Third Quarter 2016 Earnings Announcement Schedule
Nov 02, 2016 12:01 pm UTC| Business
REHOVOT, Israel, Nov. 02, 2016 -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third...